MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRAS Q61R Human Endothelial Cells
- 7 January 2026
- journal article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (3) , e70002
Abstract
Background: An activating NRAS p .Q61R ( NRAS Q61R ) somatic mutation occurs in the lesions of patients with kaposiform lymphangiomatosis (KLA). Therapies for KLA patients are limited and since the mitogen‐activated protein kinase pathway is hyperactivated by NRAS Q61R , we evaluated the potency of Mitogen‐activated protein kinase kinase (MEK) inhibitors (trametinib, selumetinib, and cobimetinib) on human NRAS Q61R endothelial cells (ECs). RNA sequencing analysis was performed to identify dysregulated genes and those restored by trametinib. Trametinib was tested in a mouse xenograft model of NRAS Q61R ECs. Procedure: Doxycycline (Dox)‐inducible NRAS Q61R ECs were treated with trametinib, selumetinib, cobimetinib, or vehicle (control). Cell signaling pathways, proliferation, migration, morphology, and angiopoietin‐2 (ANG‐2) levels were assessed. RNA‐sequencing analysis was performed on Dox‐induced NRAS wild‐type ( NRAS WT ), NRAS Q61R , and trametinib‐treated NRAS Q61R ECs. Selected proteins were verified by immunoblotting. NRAS Q61R ECs were injected into nude mice on Dox‐containing diet to generate xenografts and treated with trametinib or vehicle. Results: Trametinib reduced NRAS Q61R ‐activated ERK phosphorylation, cell proliferation, migration, spindling, and ANG‐2 at lower doses than selumetinib or cobimetinib. RNA‐sequencing detected 1315 upregulated and 1773 downregulated genes in NRAS Q61R ECs compared with NRAS WT . Trametinib corrected 19% upregulated and 8% downregulated genes, including elevated Notch ligands (DLL4, JAG1), activated Notch 1, and HES1. Trametinib reduced NRAS Q61R ECs xenograft weights by 46%, vascular area by 63%, and phosphorylated ERK staining. Conclusion: Trametinib was the most effective MEK inhibitor, correcting some dysregulated genes in NRAS Q61R ECs, including some in the Notch pathway. Trametinib reduced vessel overgrowth in xenografts of NRAS Q61R ECs. These studies support using trametinib treatment for KLA patients with an NRAS Q61R mutation.Keywords
Funding Information
- National Institutes of Health (HL156866)
This publication has 30 references indexed in Scilit:
- Human Lymphatic Endothelial Cells Expressing NRASQ61R Model Characteristics of Kaposiform LymphangiomatosisPediatric Blood & Cancer, 2025
- RAS Pathway Mutations and Therapeutics in Vascular AnomaliesPediatric Blood & Cancer, 2025
- Lyve1‐Driven NrasQ61R Causes Edema, Enlarged Lymphatic Vessels, and Hepatic Vascular Defects in Embryonic MicePediatric Blood & Cancer, 2024
- NRAS Q61R mutation drives elevated angiopoietin‐2 expression in human endothelial cells and a genetic mouse modelPediatric Blood & Cancer, 2024
- How we use angiopoietin‐2 in the diagnosis and management of vascular anomaliesPediatric Blood & Cancer, 2024
- Kaposiform lymphangiomatosis: Diagnosis, pathogenesis, and treatmentPediatric Blood & Cancer, 2023
- How we approach the diagnosis and management of complex lymphatic anomaliesPediatric Blood & Cancer, 2021
- NOTCH1: Review of its role in lymphatic development and study of seven families with rare pathogenic variantsMolecular Genetics & Genomic Medicine, 2020
- Potential biomarkers of kaposiform lymphangiomatosisPediatric Blood & Cancer, 2019
- Genotype-Guided Medical Treatment of an Arteriovenous Malformation in a ChildJAMA Dermatology, 2019